CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

October 17, 2018 Providence News Team

Patients who have relapsed or failed first-line treatment for aggressive forms of B-cell non-Hodgkin lymphoma may qualify to receive a promising CAR T-cell therapy in a new clinical trial at Providence Cancer Institute:

Study: Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-NHL-006) for B-cell non-Hodgkin lymphoma

JCAR017 is an investigational CAR T-cell therapy that modifies a patient’s own T-cells to express proteins called CARs (chimeric antigen receptors), which help T-cells recognize tumor cells and go after them. A Phase I study of JCAR017 in people with aggressive forms of B-cell lymphoma found that it provided “a durable reduction or eradication of cancer,” including complete cancer eradication in just over half of the patients. Read more in Lymphoma News Today.

CAR T-cell therapy is a major research priority for the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center. Read more about JCAR017 in Immuno-Oncology News, and find out more about adoptive T-cell therapy research at Providence.

Providence is one of only two centers in the United States currently participating in this clinical trial. For more information or to enroll a patient, call our Clinical Research office at 503-215-2614. Call us early for consideration, before the patient receives a salvage therapy or stem cell transplant.

See more studies
New research studies are added frequently. Please visit our website to see all studies in all cancer types currently open at Providence Cancer Institute.

Enter content here

About the Author

The Providence News Team brings you the updates to keep you informed about what's happening across the organizational ecosystem. From partnerships to new doctor announcements, we are committed to keeping you informed.
More Content by Providence News Team

Welcome to your journey for creating a healthier you

CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

About the Author

Previous Article

Next Article

CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

About the Author

Previous Article

Next Article

Most Recent Articles

Providence partners with TGR Foundation, a Tiger Woods Charity, to address health disparities, create career paths for youth

We are pleased to share we have rescheduled our last Neighborhood Market. It will be held Weds., October 5 in our new location--the parking lot near the Outpatient Lab.

Hear the latest news in gynecologic cancer treatments and research at a free virtual speaker series presented by Providence Foundations of Oregon and Providence Cancer Institute.

Dr. Shephal Doshi leads the nation in fixes for atrial fibrillation and arrhythmia

The Center for Maternal and Infant Care at Queen of the Valley Medical Center has been named on the Cal Hospital Compare Maternity Care Honor Roll.

The CARESTAR Foundation is pleased to announce the 2022 recipient of the Leighton Memorial Award is the Better Birthing Coalition, a local partnership between the K'ima:w Medical Center and Providence

Providence’s team of certified nursing assistants use technology to keep some of our most vulnerable patients safe, 24 hours a day, without ever stepping foot inside their rooms.

Providence hematology expert offers the most updated information about lymphoma, treatment options and helpful community resources.

Providence in Humboldt County is pleased to announce that Darian Harris has been appointed the new chief executive for Providence St. Joseph Hospital and Providence Redwood Memorial Hospital.

After making it to the top of the tallest peak, Adam knows he can handle any incline that comes his way, with our Mission family supporting him with every step.

New investigator-initiated clinical trial available only at Providence Cancer Institute will evaluate the safety and efficacy of targeted therapy combination for treating thyroid cancer.

Providence Alaska Medical Center has once again been recognized as the top health care provider in Alaska in the U.S. News & World Report 2022-2023 Best Hospitals rankings.

Providence experts share their insights on recent advances in melanoma research and care, and tips on communicating with loved ones in a live virtual symposium on Oct. 7.

Providence St. Joseph Hospital of Orange Earns Robotics Center of Excellence Designation In addition, three physicians receive Surgeons of Excellence in Robotics Surgery

Providence Alaska Medical Center has been recognized by the American College of Cardiology and American Heart Association for providing high-quality care for victims of heart disease and stroke.

Fullerton hospital named California’s only designated center of excellence for innovative robotic technique that is changing everything you thought you knew about back surgery

Providence Little Company of Mary Medical Centers earn US News rankings, rated among top hospitals in California

The 2022 Walk to Remember event will begin at 9:30 a.m. Saturday, Aug. 13, in Parking Structure 2 (PS2) at Providence Alaska Medical Center and continue to University Lake.

New Providence-sponsored study may provide new insights into the efficacy of shorter duration radiation and chemotherapy treatment before surgery for people with stage II/III rectal cancer

Providence St. Joseph Hospital Emergency Care Center Save Lives